BMAL1 regulates balance of osteogenic–osteoclastic function of bone marrow mesenchymal stem cells in type 2 diabetes mellitus through the NF-κB pathway

2018 ◽  
Vol 45 (6) ◽  
pp. 1691-1704 ◽  
Author(s):  
Xiaoguang Li ◽  
Na Liu ◽  
Bin Gu ◽  
Wei Hu ◽  
Ying Li ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Type 2 Diabetes Mellitus ◽  
Marrow Mesenchymal Stem Cells

The safety of bone-marrow derived mesenchymal stem cells in patients with type 2 diabetes mellitus

Cytotherapy ◽  
2014 ◽  
Vol 16 (4) ◽  
pp. S82 ◽  
Author(s):  
P. Adorable-Wagan ◽  
S. Bernal ◽  
D. Lavilles ◽  
M. De Vera
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Type 2 Diabetes Mellitus

scholarly journals Bone Marrow-Derived Mesenchymal Stem Cells Restored High-Fat-Fed Induced Hyperinsulinemia in Rats at Early Stage of Type 2 Diabetes Mellitus

2020 ◽  
Vol 29 ◽  
pp. 096368972090462
Author(s):  
Gongchi Li ◽  
Han Peng ◽  
Shen Qian ◽  
Xinhua Zou ◽  
Ye Du ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Type 2 Diabetes Mellitus ◽  
Early Stage ◽  
Histological Structure ◽  
High Fat

Numerous studies have proposed the transplantation of mesenchymal stem cells (MSCs) in the treatment of typical type 2 diabetes mellitus (T2DM). We aimed to find a new strategy with MSC therapy at an early stage of T2DM to efficiently prevent the progressive deterioration of organic dysfunction. Using the high-fat-fed hyperinsulinemia rat model, we found that before the onset of typical T2DM, bone marrow-derived MSCs (BM-MSCs) significantly attenuated rising insulin with decline in glucose as well as restored lipometabolic disorder and liver dysfunction. BM-MSCs also favored the histological structure recovery and proliferative capacity of pancreatic islet cells. More importantly, BM-MSC administration successfully reversed the abnormal expression of insulin resistance-related proteins including GLUT4, phosphorylated insulin receptor substrate 1, and protein kinase Akt and proinflammatory cytokines IL-6 and TNFα in liver. These findings suggested that MSCs transplantation during hyperinsulinemia could prevent most potential risks of T2DM for patients.

Impact of type 2 diabetes mellitus on the immunoregulatory characteristics of adipose tissue-derived mesenchymal stem cells

2021 ◽  
Vol 140 ◽  
pp. 106072
Author(s):  
Nourhan Abu-Shahba ◽  
Marwa Mahmoud ◽  
Alaa Mohammed El-Erian ◽  
Mohamed Ibrahim Husseiny ◽  
Ghada Nour-Eldeen ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Type 2 Diabetes Mellitus ◽  
Adipose Tissue

Transplantation of Bone Marrow Mesenchymal Stem Cells for the Treatment of Type 2 Diabetes in a Macaque Model

2013 ◽  
Vol 198 (6) ◽  
pp. 414-427 ◽  
Author(s):  
Xing-hua Pan ◽  
Qiao-qiao Song ◽  
Jie-jie Dai ◽  
Xiang Yao ◽  
Jin-xiang Wang ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Stem Cells ◽  
Bone Marrow ◽  
Mesenchymal Stem Cells ◽  
Macaque Model ◽  
Marrow Mesenchymal Stem Cells

scholarly journals Mesenchymal stem cells modified by FGF21 and GLP1 ameliorate lipid metabolism while reducing blood glucose in type 2 diabetic mice

2020 ◽  
Author(s):  
Binghua Xue ◽  
Xiuxiao Xiao ◽  
Tingting Yu ◽  
Xinhua Xiao ◽  
Jie Xie ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Type 2 Diabetes Mellitus ◽  
Stem Cell ◽  
Blood Glucose ◽  
Mouse Model ◽  
Therapeutic Effects

Abstract Objective: The purpose of this study was to investigate the therapeutic effects of genetically modified mesenchymal stem cells (MSCs) in the treatment of type 2 diabetes mellitus (T2DM) in order to identify a new method for treating diabetes that differs from traditional medicine and to provide a new means by which to fundamentally improve or treat diabetes. Methods: MSCs derived from adipose tissue were modified to overexpress FGF21 and GLP1, which was achieved through lentiviral particle transduction. The cells were transplanted into BKS.Cg-Dock7m+/+Leprdb/Nju mice (T2DM mouse model). Injections of physiological saline (0.1 mL) and liraglutide (0.5 mg/kg) were used as negative and positive controls, respectively. ELISA or Western blotting were used for protein analysis, and quantitative real-time PCR was used for gene expression analysis. Results: Genetic modification had no effects on the morphology, differentiation ability, or immunophenotype of MSCs. Moreover, MSC-FGF21+GLP1 cells exhibited significantly increased secretion of FGF21 and GLP1. In the T2DM mouse model, the transplantation of MSC-FGF21+GLP1 cells ameliorated the changes in blood glucose and weight, promoted the secretion of insulin, enhanced the recovery of liver structures, and improved the profiles of lipids. Moreover, FGF21 and GLP1 exerted synergistic effects in the regulation of glucolipid metabolism by controlling the expression of insulin, srebp1 and srebp2. Conclusion: Stem cell treatment based on MSCs modified to overexpress the FGF21 and GLP1 genes is an effective approach for the treatment of T2DM. Key words: Type 2 diabetes mellitus; Mesenchymal stem cell; FGF21; GLP1

scholarly journals Melatonin Promotes the Therapeutic Effect of Mesenchymal Stem Cells on Type 2 Diabetes Mellitus by Regulating TGF-β Pathway

2021 ◽  
Vol 9 ◽  
Author(s):  
Balun Li ◽  
Xuedi Cheng ◽  
Aili Aierken ◽  
Jiaxin Du ◽  
Wenlai He ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Stem Cells ◽  
Mesenchymal Stem Cells ◽  
Type 2 Diabetes Mellitus ◽  
Therapeutic Effect ◽  
Culture Medium ◽  
Transforming Growth Factor

Abundant evidence proves the therapeutic effect of adipose-derived mesenchymal stem cells (ADMSCs) in the treatment of diabetes mellitus. However, the problems have not been solved that viability of ADMSCs were inconsistent and the cells quickly undergo senescence after in vitro cell culture. In addition, the therapeutic effect of ADMSCs is still not satisfactory. In this study, melatonin (MLT) was added to canine ADMSC culture medium, and the treated cells were used to treat type 2 diabetes mellitus (T2DM). Our research reveals that adding MLT to ADMSC culture medium can promote the viability of ADMSCs. This effect depends on the binding of MLT and MLT receptors, which activates the transforming growth factor β (TGF-β) pathway and then changes the cell cycle of ADMSCs and improves the viability of ADMSCs. Since ADMSCs were found to be used to treat T2DM by anti-inflammatory and anti-endoplasmic reticulum (ER) stress capabilities, our data demonstrate that MLT augment several effects of ADMSCs in remission hyperglycemia, insulin resistance, and liver glycogen metabolism in T2DM patients. This suggest that ADMSCs and MLT-ADMSCs is safe and vabulable for pet clinic.

Sign in / Sign up

Export Citation Format

Share Document